

Lesotho

Population 2016

2.2 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	1.1 (0.56–1.8)	49 (26–80)
Mortality (HIV+TB only)	5.2 (3.3–7.7)	238 (148–350)
Incidence (includes HIV+TB)	16 (10–23)	724 (468–1 030)
Incidence (HIV+TB only)	12 (7.3–17)	525 (332–760)
Incidence (MDR/RR-TB)**	1.1 (0.71–1.4)	49 (32–66)

Estimated TB incidence by age and sex (thousands)*, 2016

	0-14 years	> 14 years	Total
Females	1.1 (0.67–1.5)	5 (3–7)	6.1 (3.7–8.5)
Males	1.2 (0.75–1.7)	8.6 (5.2–12)	9.9 (6–14)
Total	2.3 (1.4–3.3)	14 (8.3–19)	16 (10–23)

TB case notifications, 2016

Total cases notified	7 513
Total new and relapse	7 291
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	91%
- % pulmonary	89%
- % bacteriologically confirmed among pulmonary	56%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	46% (32–71)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.41 (0.21–0.63)

TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive	4 949	73%
- on antiretroviral therapy	4 243	86%

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			410 (330–490)
Estimated % of TB cases with MDR/RR-TB	4.8% (3.7–5.9)	14% (9.2–18)	
% notified tested for rifampicin resistance			
MDR/RR-TB cases tested for resistance to second-line drugs			
Laboratory-confirmed cases		MDR/RR-TB: , XDR-TB:	
Patients started on treatment ****		MDR/RR-TB: 238, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2015	74%	7 557
Previously treated cases, excluding relapse, registered in 2015	64%	299
HIV-positive TB cases registered in 2015	77%	5 988
MDR/RR-TB cases started on second-line treatment in 2014	64%	152
XDR-TB cases started on second-line treatment in 2014		

TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2017

National TB budget (US\$ millions)	4.7
Funding source: 17% domestic, 67% international, 16% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016




Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded
— Funded internationally
— Funded domestically